Portola Pharmaceuticals Inc Stock in 2018 Q1 Driven by Institutional Investors

June 12, 2018 - By Hazel Jackson

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Logo

Sentiment for Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals Inc (NASDAQ:PTLA) institutional sentiment decreased to 0.89 in 2018 Q1. Its down -0.47, from 1.36 in 2017Q4. The ratio dived, as 75 investment managers started new and increased positions, while 84 reduced and sold their stakes in Portola Pharmaceuticals Inc. The investment managers in our partner’s database now own: 55.00 million shares, down from 56.35 million shares in 2017Q4. Also, the number of investment managers holding Portola Pharmaceuticals Inc in their top 10 positions decreased from 6 to 3 for a decrease of 3. Sold All: 37 Reduced: 47 Increased: 55 New Position: 20.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $2.82 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

The stock increased 0.21% or $0.09 during the last trading session, reaching $42.9. About 566,110 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 7.75% since June 12, 2017 and is uptrending. It has underperformed by 4.82% the S&P500.

Analysts await Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report earnings on August, 8. They expect $-1.50 EPS, down 22.95 % or $0.28 from last year’s $-1.22 per share. After $-1.28 actual EPS reported by Portola Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 17.19 % negative EPS growth.

Fernwood Investment Management Llc holds 4.17% of its portfolio in Portola Pharmaceuticals, Inc. for 228,873 shares. Partner Fund Management L.P. owns 5.33 million shares or 3.53% of their US portfolio. Moreover, Partner Investment Management L.P. has 2.55% invested in the company for 72,284 shares. The New York-based Cadian Capital Management Lp has invested 2.19% in the stock. Harvey Capital Management Inc, a Florida-based fund reported 158,580 shares.

Since January 1, 0001, it had 0 buys, and 3 selling transactions for $838,772 activity.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Ratings analysis reveals 80% of Portola Pharma’s analysts are positive. Out of 5 Wall Street analysts rating Portola Pharma, 4 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $46 while the high is $80.0. The stock’s average target of $60 is 39.86% above today’s ($42.9) share price. PTLA was included in 13 notes of analysts from December 13, 2017. The company was maintained on Monday, January 15 by Oppenheimer. Morgan Stanley maintained the stock with “Overweight” rating in Thursday, February 22 report. The firm has “Buy” rating given on Friday, May 4 by Cowen & Co. On Tuesday, December 19 the stock rating was maintained by Oppenheimer with “Buy”. As per Tuesday, March 13, the company rating was maintained by Oppenheimer. Oppenheimer maintained the shares of PTLA in report on Thursday, May 17 with “Buy” rating. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Outperform” rating given on Wednesday, February 21 by Credit Suisse. The firm has “Buy” rating given on Thursday, December 28 by Oppenheimer. As per Thursday, March 1, the company rating was downgraded by Morgan Stanley. As per Wednesday, December 13, the company rating was maintained by Oppenheimer.

More notable recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Fool.com which released: “Is an Acquisition in Portola Pharmaceuticals’ Future?” on June 06, 2018, also Seekingalpha.com with their article: “Portola Pharmaceuticals’ (PTLA) CEO William Lis on Q1 2018 Results – Earnings Call Transcript” published on May 15, 2018, Streetinsider.com published: “Portola Pharma (PTLA) Announces Retirement of CEO Bill Lis” on June 04, 2018. More interesting news about Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were released by: Seekingalpha.com and their article: “Buy Diamondback Energy On Declines – Cramer’s Lightning Round (5/11/18)” published on May 14, 2018 as well as Globenewswire.com‘s news article titled: “Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018” with publication date: June 04, 2018.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: